|
Post by avichen on Sept 23, 2016 12:10:48 GMT -5
|
|
|
Post by kbrion77 on Sept 23, 2016 12:22:44 GMT -5
This thread will go over real well. I DETEST your sarcasm amidst true Longs losing more money and PWD being in jeopardy of not having access to Afrezza because of an incompetent CEO unwilling to lead by example thereby jeopardizing many years of R&D by someone who actually gave a damn...Al Mann. We have heard for a year about your despise for Matt P and most recently game over for MNKD and Afrezza and quite honestly it's annoying. There are probably 15 true longs on this board but I don't feel bad for any of us. We have all had the opportunity to sell out when times were tough and rid ourselves of gut wrenching days like today. There will be a lot of lessons to be learned either way if MNKD succeeds or fails but I would say if MNKD and Afrezza do fail than the #1 lesson will be to keep emotions out of your investments.
|
|
|
Post by victoria on Sept 23, 2016 12:40:12 GMT -5
Well, I hear the pain of all of us with paper losses, or actual losses for those who close their positions. I still see this as a high risk stock, ie one which may go up or may fail entirely, I do not yet see MNKD as certain to fail, and at this stage with paper losses several multiples of 100k USD it would be pointless for me to sell my long option positions since the yield would be trivial. NRx today best since Feb. TRx best since June. Good things happening under Dr Castagna. Positive serious journal pieces. Expected label revision application very soon. I am staying. Its the same drug I originally invested in, after all.
|
|
|
Post by cgiscgis on Sept 23, 2016 12:44:26 GMT -5
The board of directors completely failed and must be replaced.
|
|
|
Post by slugworth008 on Sept 23, 2016 12:47:42 GMT -5
Fellow Longs, today marks the day we should all face the facts...MannKind is done. Since August 2015 I believed (& bought; ultimately I've lost -$35k+) Afrezza/Technosphere could improve patients lives and change modern medicine. Unfortunately no amount of good news (the script uptrend, that supposed MLB advertising bullsh*t which will not happen, the stellar ADA+JDRF reviews, etc) can save this company. It is too little to late especially with the staggering & unrelenting short position. Liane can edit & delete posts hiding the scary truth: management squandered a golden opportunity, failed patients and screwed shareholders forever. Only a miracle like Novo Nordisk could save MannKind now and we all know that is not happening. This is a tragic damn shame how this story ended: PWD around the world will never discover the benefits of Afrezza. Big bio-pharma buried disruptive innovation and shorts have won. trondisc, I sympathize with your frustration and anger but you're taking today's share price as clear evidence that it is over. I dont think it is. You didnt say if your loss is on paper or you sold your position and incurred an actual loss;there is a big difference. I warned everyone in a post around the time of the second launch to be prepared for more punishment to the stock price to discourage us especially as scripts begin to turn around. That seems to be exactly what has happened today. I expect it to get even more brutal... forewarned is forarmed. Here, here, well said!
|
|
|
Post by rockstarrick on Sept 23, 2016 12:50:30 GMT -5
The last time we set our new low of .64 when sanofi bailed I left myself 2 choices. 1) sell all and move on, or 2) buy more to trade and try to recover some of my $$$. I chose to buy 10,000 shares @.65, I later sold all 10,000 for $2.20 and recouped a good portion of my lost $$$. I had another order @.65 that filled this morning, I am fairly confident I will lock in more gains with these shares, time will tell. I guess my point is...... I am a faithful Mnkd "long" with my original core, but when the opportunity presents itself, I use it to my advantage. Mnkd shares @ .65, I'll play that game every time. Best of luck to you Rock
|
|
|
Post by LosingMyBullishness on Sept 23, 2016 13:09:46 GMT -5
did you sell your 100% position today? if so good luck on your next journey. I guess the script growth disappointed you and not meet your expectations. They were ok considering the decline in the last few months ( not when taking the runway ahead into consideration?) Price is truth. Guess you believe we're going to see $1 even $2 again someday. Gut check time. Face reality please, an improving script trend DOES NOT MEAN this company will survive. Even though Afrezza is the best insulin on the market, NO large cap bio-pharma will buy otherwise it would have happened already. Price is truth.. argh. IMO you misunderstand the importance of scripts: script increase is to proof the market to partners. This is what you can achieve with the present sales force if the product is good. So IMO script counts do not have to get to a break even. Remember that for most biotechs successful trials are all what it takes to find a partner.
|
|
|
Post by cjm18 on Sept 23, 2016 13:26:33 GMT -5
All these "positive" turn of events the last several months you are posting AND YET the price continues to dwindle downward. Are you really that f*cking delusional?!? trondisc is right. All of these "positive" turn of events mean nothing. This drug needed to be marketed directly to the patients. Doctor's are not Afrezza friendly. Most of the patients using this drug had to pressure their doctor to let them try Afrezza. Google trends is not 100% accurate but a least it can provide an indication of interest and according to google there has been no up-tick in Afrezza related searches. I won't give this management credit for a label change until they receive one. What exactly is the label change going to say? Doctors already know it works faster than any other insulin. And if the FDA rejects the label change the stock is going to take another hit. Mannkind needs to advertise this drug and stop all the have measures. They need advertising you say. Pretty sure I mentioned that as a positive. It's on the horizon. Most of the other positives matter to another entity who would buy or cash infuse or invest into this venture. Which is the only way to avoid dilution or taking out a loan. Working with a very credible group like jdrf so this drug can be used by kids (who don't like needles) isn't a big deal? Do you really think another entity was more likely to extend us a loan right after sny dropped us and we were bleeding scripts? We are better off now. Will we better off in 3 months if refill rate doesn't pick up? No. But does a lower share price impact mannkind's ability to get the refill rate up? No. The label change will allow advertising and the website to say the only ultra rapid acting insulin in the world. Big pharma might like that.
|
|
|
Post by cjm18 on Sept 23, 2016 13:31:11 GMT -5
Price is truth. Guess you believe we're going to see $1 even $2 again someday. Gut check time. Face reality please, an improving script trend DOES NOT MEAN this company will survive. Even though Afrezza is the best insulin on the market, NO large cap bio-pharma will buy otherwise it would have happened already. Price is truth.. argh. IMO you misunderstand the importance of scripts: script increase is to proof the market to partners. This is what you can achieve with the present sales force if the product is good. So IMO script counts do not have to get to a break even. Remember that for most biotechs successful trials are all what it takes to find a partner. Ding ding. We don't have to get enough scripts to cover the full burn rate to be successful. Do you really think Mnkd thought a 70 person team would do that alone? That would be unreasonable. Irrational. Insane.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 23, 2016 13:39:50 GMT -5
Price is truth.. argh. IMO you misunderstand the importance of scripts: script increase is to proof the market to partners. This is what you can achieve with the present sales force if the product is good. So IMO script counts do not have to get to a break even. Remember that for most biotechs successful trials are all what it takes to find a partner. Ding ding. We don't have to get enough scripts to cover the full burn rate to be successful. Do you really think Mnkd thought a 70 person team would do that alone? That would be unreasonable. Irrational. Insane. Can they afford to hire 700? With the foot print analysis and budget, 70 probably 60 were placed
|
|
|
Post by rombic33 on Sept 23, 2016 13:50:19 GMT -5
70 people to visit (aka hire) 100/200/300 doctors weekly who can-want-have patients to prescribe. So in a month it's more than 700 of possibilities.
|
|
|
Post by slugworth008 on Sept 23, 2016 14:29:33 GMT -5
The last time we set our new low of .64 when sanofi bailed I left myself 2 choices. 1) sell all and move on, or 2) buy more to trade and try to recover some of my $$$. I chose to buy 10,000 shares @.65, I later sold all 10,000 for $2.20 and recouped a good portion of my lost $$$. I had another order @.65 that filled this morning, I am fairly confident I will lock in more gains with these shares, time will tell. I guess my point is...... I am a faithful Mnkd "long" with my original core, but when the opportunity presents itself, I use it to my advantage. Mnkd shares @ .65, I'll play that game every time. Best of luck to you Rock I'm right there with ya Rock! After my house closes (I just bought a house in Portland, OR and am heading home after 23 years in the atl) - I'll be following suit with ya.
|
|
|
Post by gonetotown on Sept 23, 2016 17:59:29 GMT -5
I can't help but get the feeling that they are planning on a voluntary chapter 11 reorganization. As someone here pointed out, they likely need a certain minimum number of millions of dollars just to begin the process. According to "Spencer Osborne" on SA, Mannkind is down to less than 15 million in available cash. With today's closing price the ATM is worth only about 15 miilion. There doesn't seem to be much hope of generating any decent cash flow from afrezza anytime soon. To save the company, the most logical thing would be to file banktuptcy, reorganize and trade new shares for debt, and emerge with new majority holders, no debt, and maybe enough money to keep going a while longer.
|
|
|
Post by kball on Sept 23, 2016 18:09:47 GMT -5
^ This would come as a complete surprise to folks here.
|
|
|
Post by boytroy88 on Sept 23, 2016 19:31:07 GMT -5
I can't help but get the feeling that they are planning on a voluntary chapter 11 reorganization. As someone here pointed out, they likely need a certain minimum number of millions of dollars just to begin the process. According to "Spencer Osborne" on SA, Mannkind is down to less than 15 million in available cash. With today's closing price the ATM is worth only about 15 miilion. There doesn't seem to be much hope of generating any decent cash flow from afrezza anytime soon. To save the company, the most logical thing would be to file banktuptcy, reorganize and trade new shares for debt, and emerge with new majority holders, no debt, and maybe enough money to keep going a while longer. How would that affect the shares that the employees and foundations own? I can't see ch11 happening unless the employees and foundations shares are exempt... And if that is the case they are going to face a heck of a lawsuit from the share holders that were left out in the cold.
|
|